Ahlmark G, Saetre H
Eur J Clin Pharmacol. 1976 Jun 15;10(2):77-83. doi: 10.1007/BF00609463.
162 patients discharged from hospital after mycardial infarction were randomly allocated to two groups, one received alprenolol 400 mg daily and the other served as the control. The period of follow-up was two years and all other treatment given was standardized. The two groups did not differ with respect to risk factors for myocardial infarction, the course of the acute infarct or treatment during follow-up. After two years one patient in the group treated with alprenolol had died suddenly as compared to nine in the control group. During the same period four fresh infarcts had occurred in the alprenolol group compared to 15 in the control group. Both these differences were statistically significant. Only four patients were obliged to discontinue beta-blocker treatment because of suspected side-effects. Long-term post-infarction treatment with beta-blockers appears to be an effective form of secondary therapy without serious side-effects.
162名心肌梗死后出院的患者被随机分为两组,一组每天服用400毫克阿普洛尔,另一组作为对照组。随访期为两年,所有其他给予的治疗均标准化。两组在心肌梗死的危险因素、急性梗死病程或随访期间的治疗方面没有差异。两年后,服用阿普洛尔治疗的组中有1名患者突然死亡,而对照组有9名。在同一时期,阿普洛尔组发生了4例新的梗死,而对照组为15例。这两个差异均具有统计学意义。只有4名患者因疑似副作用而不得不停止β受体阻滞剂治疗。心肌梗死后长期使用β受体阻滞剂治疗似乎是一种有效的二级治疗形式,且无严重副作用。